GlycoMimetics, Inc.
Index- P/E- EPS (ttm)-1.03 Insider Own1.50% Shs Outstand52.42M Perf Week4.65%
Market Cap110.25M Forward P/E- EPS next Y-0.65 Insider Trans84.19% Shs Float51.08M Perf Month225.05%
Income-53.90M PEG- EPS next Q-0.21 Inst Own53.40% Short Float / Ratio1.16% / 1.66 Perf Quarter206.12%
Sales0.09M P/S1190.28 EPS this Y-10.50% Inst Trans-2.26% Short Interest0.59M Perf Half Y248.84%
Book/sh0.92 P/B2.45 EPS next Y28.60% ROA-72.60% Target Price8.00 Perf Year47.06%
Cash/sh1.05 P/C2.14 EPS next 5Y- ROE-85.00% 52W Range0.51 - 2.49 Perf YTD56.25%
Dividend- P/FCF- EPS past 5Y3.80% ROI-77.80% 52W High-15.66% Beta2.41
Dividend %- Quick Ratio6.90 Sales past 5Y128.80% Gross Margin- 52W Low311.76% ATR0.21
Employees52 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)67.22 Volatility11.85% 15.44%
OptionableYes Debt/Eq0.00 EPS Q/Q51.60% Profit Margin- Rel Volume2.41 Prev Close2.25
ShortableYes LT Debt/Eq0.00 EarningsNov 09 BMO Payout- Avg Volume358.23K Price2.10
Recom1.70 SMA2020.04% SMA5095.13% SMA200138.22% Volume361,125 Change-6.67%
Nov-12-21Upgrade Jefferies Hold → Buy $3 → $4
Nov-14-19Initiated ROTH Capital Buy $12
Aug-05-19Downgrade SunTrust Buy → Hold $23 → $5
Aug-05-19Downgrade Piper Jaffray Overweight → Neutral $20 → $6
Aug-05-19Downgrade Jefferies Buy → Hold
Apr-12-19Initiated Piper Jaffray Overweight $20
Dec-18-18Initiated H.C. Wainwright Buy $24
Jul-26-16Initiated SunTrust Buy
Mar-17-15Reiterated Stifel Buy $13 → $14
Dec-02-22 01:18PM
Nov-23-22 09:55AM
Nov-16-22 09:40AM
Nov-12-22 07:14AM
09:12AM Loading…
Nov-10-22 09:12AM
Nov-09-22 07:00AM
Nov-08-22 04:05PM
Nov-03-22 09:00AM
Nov-02-22 07:00AM
Oct-10-22 11:57PM
Oct-04-22 12:00PM
Sep-09-22 08:30AM
Sep-07-22 07:00AM
Sep-06-22 07:00AM
12:00PM Loading…
Aug-09-22 12:00PM
Aug-03-22 02:00PM
Jul-27-22 04:00PM
Jul-18-22 10:22AM
Jun-03-22 08:36AM
Jun-02-22 04:00PM
Apr-28-22 06:30PM
Apr-25-22 09:00AM
Mar-08-22 04:30PM
Mar-03-22 04:15PM
Mar-02-22 09:15AM
09:00AM Loading…
Feb-25-22 09:00AM
Feb-23-22 04:30PM
Dec-13-21 09:00AM
Dec-06-21 09:15AM
Nov-24-21 08:00PM
Nov-23-21 04:30PM
Nov-22-21 04:15PM
Nov-15-21 07:00AM
Nov-11-21 09:00AM
Nov-09-21 09:00AM
Nov-02-21 02:00PM
Oct-26-21 09:00AM
Sep-29-21 01:14PM
Sep-24-21 06:57AM
Sep-23-21 04:00PM
Sep-10-21 08:10AM
Sep-08-21 09:00AM
Aug-23-21 08:38AM
Aug-09-21 09:00AM
Aug-07-21 12:00PM
Aug-05-21 07:30AM
Aug-04-21 04:15PM
Jul-29-21 04:30PM
Jul-22-21 09:00AM
Jul-12-21 09:00AM
May-27-21 07:08PM
May-26-21 09:00AM
May-20-21 08:11AM
May-13-21 11:15AM
May-12-21 02:13AM
May-05-21 06:03AM
May-03-21 02:30PM
Apr-26-21 09:00AM
Apr-10-21 09:00AM
Mar-31-21 04:48PM
Mar-10-21 04:30PM
Mar-04-21 08:30AM
Mar-02-21 05:30PM
Feb-26-21 04:30PM
Feb-24-21 12:46AM
Feb-23-21 04:30PM
Jan-10-21 03:25AM
Jan-07-21 07:10AM
Dec-11-20 08:32PM
Dec-07-20 04:30PM
Dec-05-20 06:00PM
Nov-26-20 12:40AM
Nov-10-20 04:00PM
Nov-06-20 07:31PM
Nov-04-20 01:03PM
Oct-30-20 09:00AM
Oct-26-20 09:00AM
Oct-12-20 07:28AM
Oct-06-20 10:31AM
Oct-05-20 04:30PM
Sep-08-20 04:00PM
Sep-04-20 09:00AM
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JUNIUS DANIEL MDirectorNov 17Buy1.8720,00037,40063,250Nov 18 04:01 PM
Rock EdwinChief Medical OfficerNov 15Buy1.66100,000166,000200,000Nov 16 04:26 PM
Rock EdwinChief Medical OfficerNov 14Buy1.43100,000143,000100,000Nov 16 04:26 PM
Hahn Brian M.SVP Finance, CFONov 11Buy1.0620,00021,20056,843Nov 14 04:13 PM
PEARSON TIMOTHY RDirectorNov 11Buy1.2919,40025,02624,650Nov 14 04:14 PM
Semerjian HaroutChief Executive OfficerNov 11Buy1.2925,00032,25025,000Nov 14 04:13 PM
Magnani John L.SVP of Research, CSONov 11Buy1.1745,04552,703366,078Nov 14 04:11 PM
Girard ArmandSVP, Chief Business OfficerNov 11Buy1.056,5006,82529,161Nov 14 04:04 PM
Magnani John L.SVP of Research, CSOMar 09Sale1.093,2273,517321,033Mar 10 05:06 PM
Girard ArmandSVP, Chief Business OfficerMar 09Sale1.092,3392,55022,661Mar 10 05:05 PM
Hahn Brian M.SVP Finance, CFOMar 09Sale1.092,9173,18036,843Mar 10 05:03 PM